Promoter hypermethylation of the cyclin-dependent kinase inhibitor (CDKI) gene p21WAF1/CIP1/SDI1 is rare in various lymphomas and carcinomas.
from its regulation of CDK 2 in the nucleus. 9 Therefore, the role of p27 in the pathogenesis of myeloma requires further study.
Lastly, the infrequent p57 methylation in patients with MM is similar to another study, which showed p57 methylation in only four (15.4%) of 26 myeloma patients. 10 Moreover, gene silencing associated with methylation was demonstrated in WL2 cell line, in which demethylation led to re-expression of p57 transcript.
In conclusion, in contrast to frequent methylation of p15 and p16, both CKI members of the INK4 family, we showed the absence of p21 and p27 methylation and infrequent p57 methylation in 55 patients with MM. This is also consistent with the absence of p21 and p27 methylation, and the infrequent methylation of p57 in myeloma cell lines. Our data suggested that epigenetic dysregulation of the INK4 family, instead of the CIP/KIP family of CKI, is the predominant mechanism to abrogate negative regulation of the G 1 S cell cycle control in MM. This is consistent with recent data showing an essential role of CDK4 but not CDK2 in cell proliferation.
11
Acquired Isodisomy for chromosome 13 is common in AML, and associated with FLT3-itd mutations Leukemia (2005) The FMS-like tyrosine kinase 3 (FLT3) gene in chromosome band 13q12, encodes a tyrosine kinase receptor.
1 FLT3 mutations are common in acute myeloid leukaemia (AML), most often an internal tandem duplication (itd), and are associated with a poor prognosis.
1-6 FLT3-itd mutations can be detected by PCR of genomic DNA. 1, 3 Some patients show excess dosage of the FLT3-itd allele, or apparent complete loss of the FLT3 wild-type (wt) gene, [1] [2] [3] [4] [5] [6] and this has been associated with a more adverse prognosis. [3] [4] [5] The mechanism for excess dosage is not known, although cryptic deletions of the FLT3-wt region, 3, 4 acquired isodisomy (AI) for chromosome 13, 4 or segmental AI through homologous somatic recombination, 5 have been suggested. This uncertainty with respect to the mechanism confounds analysis of prognostic impact within this potential subgroup of FLT3-itd patients as stratification without knowledge of the mechanism may be inaccurate. We investigated these mechanisms and demonstrated AI for chromosome 13 (AI-13) to be the most likely cause of FLT3-itd excess dosage.
In all, 148 consecutive confirmed AML patients, at diagnosis (144) or relapse (four), with normal karyotypes were investigated at two centres. DNA was extracted using Puregene kits (Gentra Systems, Minneapolis, USA) from fresh samples; or from fixed (3:1 methanol:acetic acid) cytogenetic cell pellets using a modified standard phenol/chloroform extraction. FLT3-itd status was determined by semi-quantitative PCR of genomic DNA using published primers 3 for exons 14 and 15 and the intervening intron, 7 with fragment sizing on a fluorescent capillary sequencer (Beckman Coulter CEQ8000 or Applied Biosystems 3100). Selected patients were analysed for variation in allele dosage of short tandem repeat (STR) DNA microsatellite markers on chromosome 13 by PCR and fragment sizing on a Beckman CEQ8000 using a modified QF-PCR protocol.
8 FLT3-itd mutations were identified in 51/148 (34%) patients, with 8/51 (16% of FLT3-itd cases) having a FLT3-itd to FLT3-wt ratio greater than 1, implying increased copy number for FLT3-itd or decreased copy number for the FLT3-wt (Figure 1 ). Brief clinical details and outcomes for the patients with excess FLT3-itd dosage are shown in Table 1 . Patient 1 and 2 did not have a FLT3-itd mutation at presentation. The overall survival for patient 1 was 24 months, however, survival post second relapse, when AI-13 and FLT3-itd was detected, was only 1 month. The only surviving patient (patient 2) is post stem cell transplant (SCT) in second remission. Interphase FISH on patients 1, 2 and 3 with Vysis LSI 13 (RB1) 13q14 probes (Vysis, Downers Grove, and 299, with a ratio of 9.1, and a stutter artefact at 295. (e) patient 2 with peaks at 264 and 268, with a ratio of 7.9 (after adjustment for stutter); the unlabelled peak at 264 includes a stutter contribution from the 268 allele, but the constitutional allele pattern was confirmed as 264 and 268 by analysis of a remission sample. (f) patient 3 with peaks at 268 and 285, with a ratio of 2.4. Each sample represents a mixture of both normal and leukaemia cells. The smaller peak is derived from one chromosome 13 from the normal cells; and the larger peak is derived from the other chromosome 13 from the normal cells together with the corresponding chromosome 13 from the leukaemia cells. The other chromosome 13 allele from the leukaemia cells must be absent, otherwise the allele dosage ratio would remain as 1. NA -data not available at time of submission. FLT3-itd to FLT3-wt ratios calculated from peak heights by dividing the FLT3-itd peak by the FLT3-wt peak.
Correspondence IL, USA) showed no evidence of cryptic gain or loss of chromosome 13. Short arm and satellite polymorphisms on these three patients were also investigated for cytogenetic evidence of isodisomy, but were not informative with the chromosome morphology and resolution obtained. Six of eight patients had unequal allele dosage on STR analysis at several loci ( Figure 1 and Table 2 ). The expected ratio between the peak heights of the alleles is 1. The ratios 41 indicate an increase in the copy number of that region of one chromosome 13 relative to the other, for multiple loci spread along chromosome 13. The ratios correlated reproducibly within each patient. Although interpretation of the ratios is complicated by the presence of normal cells, which contribute equally to both alleles at each loci, the presence of normal cells is helpful in demonstrating constitutional heterozygosity for a particular STR marker. Submicroscopic deletion of the FLT3-wt gene region cannot explain the unequal allele dosage as such deletions would not affect loci outside the putative deleted region. Two of eight patients had only one allele at each locus, which could represent uninformative loci, or loss of heterozygosity. However, an unpublished prenatal diagnosis audit, within one laboratory, of four of the STR markers (D13S742, D13S305, D13S634, D13S628), has shown the frequency with which these are all uninformative to be less than 1/300. Therefore, homozygosity at all six loci is likely to represent loss of heterozygosity (LOH) at some or all loci, consistent with deletions or AI-13, rather than uninformative STR markers. Remission DNA was available only for patient 2, in whom constitutional heterozygosity for D13S742 and D13S762 was confirmed.
The most likely explanation for the FLT3 and STR results in all eight patients is loss of the FLT3-wt chromosome 13 and gain of a second FLT3-itd chromosome 13, effectively AI-13. As confirmation patients 1, 2 and 3 were tested using the Affymetrix GeneChip 10k 2.0 SNP array (Affymetrix Inc., Santa Clara). Results for patients 1 and 2 suggested LOH for all loci along the whole of chromosome 13, but with a copy number of 2, implying two copies of the same chromosome 13. Patient 3 was inconclusive, possibly as a consequence of a higher proportion of normal cells, subclonal variation or limited segmental isodisomy.
The FLT3-itd:FLT3-wt and STR allele dosage ratios were used to predict the proportion of leukaemia cells based on the AI-13 model (Table 3 ). In 3/5 patients, with percentage leukaemia blasts by morphology available, there was good correlation between both predictions and percentage blasts by morphology. For patient 3 and 7 the correlation is not close, suggesting coexistence of both a FLT3-itd/FLT3-wt precursor clone and a FLT3-itd/FLT3-itd AI-13 subclone.
Seven of eight patients have died ( Table 1) . The four deceased patients for whom survival data was available died within 4 months of presentation, or of the relapse when AI-13 was detected, consistent with the more adverse prognosis in this group suggested in other studies. [3] [4] [5] In Whitman seven of eight patients with apparent complete loss of FLT3-wt died within 12 months. 4 In Thiede 14/15 patients with loss of FLT3-wt or a FLT3-itd:FLT3-wt ratio 42 died within 12 months, with the sole survivor having had a SCT. 5 Our surviving patient is also post SCT. These two survivors offer the hope that prognosis in patients with FLT3-itd and AI-13 may not be as severe in the post-SCT setting. We suggest that FLT3-itd patients comprise two subgroups: one with single mutations and retention of FLT3-wt; and the other with double mutations, primarily homozygous due to AI-13, but also including those with two independent NA -data not available at time of submission. FLT3-itd prediction of percentage leukaemia based on (100(N)/(N+1)) where N is the FLT3-itd:FLT3-wt ratio. STR prediction of percentage leukaemia based on (100(NÀ1)/(2+(NÀ1))) where N is the median ratio of the larger to smaller peak heights.
mutations. 3 The double mutation group may have a particularly adverse prognosis, [3] [4] [5] and conversely for a single FLT3-itd there may be less prognostic impact than has previously been suggested.
The frequency of FLT3-itd and AI-13 in this study is 8/148 (5%), however, this is likely to be an underestimate as excess FLT3-itd allele dosage may be masked by the presence of normal cells, 3 or by preferential PCR amplification of the smaller FLT3-wt product (particularly with larger itds). Assuming 40% of AML have normal karyotypes, the frequency of AI-13 may be at least 2% of all AML, and is likely to be considerably higher. As AI-13 in association with FLT3-wt loss must be a secondary event, then the incidence of AI-13 in relapse patients may be higher than that at diagnosis, as reported for FLT3-itd excess dosage by Schnittger (17% of FLT3-itd positive cases at presentation, 84% at relapse). 6 In our study of 18 FLT3-itd patients identified in one centre, 1/15 FLT3-itd positive patients at presentation had FLT3-itd excess dosage and AI-13, and 2/3 FLT3-itd positive patients at relapse.
Segmental and whole chromosome AI for several chromosome regions has recently been reported in AML. 9 The presence of AI is unlikely to be a benign phenomenon. It probably represents a mechanism for doubling an oncogenic event (activated oncogene or inactivated tumour suppressor gene) without the deleterious affects on cell viability of any associated genomic imbalance involved in simple gain or loss of chromosome material. As AI is cytogenetically and FISH cryptic, and may represent a subgroup of normal karyotype AML (or those with abnormal karyotypes) with a different prognosis, then appropriate screening methods need to be developed. The STR allele dosage strategy in this study offers a cost-effective solution for targeted screening for AI-13, with an advantage that the presence of normal cells assists rather than hinders the analysis. In addition, appropriate STR markers for chromosome 13 are already in use in many genetic laboratories for prenatal diagnosis or post-SCT chimaerism analysis. Microarray based SNP analysis offers a global genome approach for AI analysis, 9 but may be less tolerant of background normal cells. As AI other than AI-13 occurs in AML global screening for AI may become part of routine diagnostic testing in patients with leukaemia.
